CANADA LIFE ASSURANCE Co Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

CANADA LIFE ASSURANCE Co grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 22,436 shares of the biopharmaceutical company’s stock after acquiring an additional 938 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Intra-Cellular Therapies were worth $1,873,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in ITCI. China Universal Asset Management Co. Ltd. boosted its position in Intra-Cellular Therapies by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after purchasing an additional 2,157 shares in the last quarter. Barclays PLC boosted its position in shares of Intra-Cellular Therapies by 282.0% in the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after buying an additional 25,435 shares in the last quarter. Oak Ridge Investments LLC grew its stake in Intra-Cellular Therapies by 74.1% in the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after acquiring an additional 8,440 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Intra-Cellular Therapies by 3.3% during the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock valued at $43,735,000 after acquiring an additional 18,865 shares in the last quarter. Finally, Merit Financial Group LLC acquired a new position in Intra-Cellular Therapies during the fourth quarter worth about $206,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI opened at $131.87 on Monday. The firm has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98. The company’s 50 day moving average price is $131.16 and its 200 day moving average price is $108.51.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. StockNews.com initiated coverage on Intra-Cellular Therapies in a research report on Monday, April 21st. They issued a “hold” rating on the stock. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Eleven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies presently has an average rating of “Hold” and an average target price of $109.70.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.